Introduction
Common variable immunodeficiency (CVID) is a disorder characterized by a failure of functional antibody production, leading to recurrent bacterial infections.' In the UK there are an estimated 800-1000 patients, although the number may be much higher as accurate figures are not yet available. Onset may be at any age, although there are peaks of incidence in early childhood and early adulthood. The cause is unknown. The usual presentation is with recurrent sinopulmonary infections. In 20% of patients, autoimmune phenomena occur, including haemolytic anaemia, thrombocytopenia, neutropenia and thyroid disease. Autoantibodies may occur but are difficult to detect. Gastritis also occurs but is not associated with anti-parietal cell antibodies. Vitiligo and alopecia areata have been reported in this condition: Ipp & Gelfand report three hypogammaglobulinaemic patients, one of whom had the congenital (X-linked) form, with alopecia totalis. 3 We now report three cases of CVID accompanied by alopecia, in one case also by vitiligo, and one case of vitiligo alone. We discuss the aetiology of these conditions in the light of their occurrence in immunodeficient patients.
Case reports Case I
A man, born in 1959, first presented aged 4, when he underwent a tonsillectomy. Following this, he was troubled by recurrent 'sterile' knee effusions, and joint stiffness throughout childhood. He had infectious hepatitis in 1969, and in 1970 diabetes mellitus was diagnosed and he was commenced on insulin. Recurrent sinopulmonary infections and steatorrhoea began at this time, and during investigation in 1978, hypogammaglobulinaemia was noted. Replacement therapy was not started until 1983, when he contracted a serious salmonella infection in Portugal, followed by a perirectal abscess, which required surgical drainage. In the same year, alopecia was noted and progressed to total hair loss. His mean cell volume (MCV) was elevated and a diagnosis of pernicious anaemia made with autoantibodies only to intrinsic factor. Replacement vitamin B12 therapy was begun. He was then given intravenous immunoglobulin [IVIg] therapy, 12 g/three weekly, and more recently, 25 g/two weekly. During IVIg therapy there has been no effect on hair growth. He still occasionally has low serum levels of calcium, magnesium, zinc and iron; his diarrhoea fluctuates, but no parasites have been identified in the stool. He has a severe arthropathy, with effusions, and progressive flexion contractures of both elbows. This patient has been reported previously in the context of his salmonellosis. 16 It is thought that abnormalities of cell-mediated immunity may be involved in alopecia, although the evidence is not compelling.'7 Hair growth may return spontaneously or be induced by minoxidil. Initially this was thought to be due to local vasodilatory action, but minoxidil has also been shown to have immunomodulatory functions.18 Thus, there is only circumstantial evidence directly linking alopecia and vitiligo to specific alterations in autoimmunity.
The incidence ofautoimmunity in CVID is about 20%, based on an extensive review of 103 patients seen at a clinic in New York. Six per cent had more than one autoimmune disorder, but haematological abnormalities comprised the bulk of instances of autoimmunity; organ-specific autoim- following multiple viral infections,' and the occurrence of alopecia and vitiligo in CVID may be through infection rather than the primary immune defect, even though the infections that these patients suffer are mainly bacterial. All the patients that we report here have had major infective problems.
Previous reports have speculated that the alopecia might result from adverse reactions to intramuscular therapy.3'4 This is highly unlikely, as none of the patients described here have had any significant adverse reactions to immunoglobulin therapy. There is no evidence from these 4 cases that aggressive treatment with intravenous immunoglobulin has any effect on the alopecia or vitiligo.
